Arcturus Therapeutics (NASDAQ:ARCT) Price Target Raised to $8.00

Arcturus Therapeutics (NASDAQ:ARCT) had its price target upped by Citigroup from $7.00 to $8.00 in a research note released on Wednesday,Benzinga reports. The firm currently has a neutral rating on the biotechnology company’s stock.

ARCT has been the topic of several other research reports. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright cut their price objective on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Piper Sandler reduced their price objective on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Finally, Roth Mkm began coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $20.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.33.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $7.11 on Wednesday. The business has a 50-day moving average of $7.32 and a 200 day moving average of $11.25. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17. The firm has a market cap of $202.07 million, a P/E ratio of -2.99 and a beta of 2.40.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The business had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $14.32 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. As a group, research analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of the company. ARK Investment Management LLC grew its stake in Arcturus Therapeutics by 39.4% during the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after acquiring an additional 738,378 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Arcturus Therapeutics by 1,371.4% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after purchasing an additional 514,652 shares in the last quarter. Millennium Management LLC purchased a new stake in Arcturus Therapeutics in the 1st quarter worth approximately $4,892,000. Bank of America Corp DE boosted its holdings in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Arcturus Therapeutics by 170.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company’s stock valued at $2,398,000 after purchasing an additional 246,499 shares during the period. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics News Roundup

Here are the key news stories impacting Arcturus Therapeutics this week:

• Positive Sentiment: Company will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 11), giving management a near‑term opportunity to provide program updates and financing/cost‑pathway clarity that could stabilize sentiment. Arcturus Therapeutics to Attend Upcoming Investor Conference
• Neutral Sentiment: Citigroup cut its price target from $66 to $21 but maintained a “buy” rating — this reduces a high upside anchor and likely tempers conviction among momentum buyers, though the maintained buy stance leaves room for positive reaction if management news is constructive. Citi price target cut coverage
• Neutral Sentiment: Short‑interest data published for early March appears to be erroneous (shows 0 shares / NaN changes); investors should treat those metrics with caution until corrected — unreliable short data reduces clarity on potential short‑squeeze dynamics. (Source: market data entries)
• Negative Sentiment: HC Wainwright materially lowered EPS forecasts across 2026–2030 (e.g., FY2026 cut to ($3.07) from ($2.19); FY2029 and FY2030 swung to large expected losses), and reduced quarterly EPS estimates for Q1–Q4 2026 — this increases downside pressure by signaling a longer path to profitability and higher cash burn assumptions. HC Wainwright estimate revisions (market summary)
• Negative Sentiment: Recent Q4 earnings commentary and third‑party assessments highlighted missed revenue and EPS vs. expectations, reinforcing short‑term weakness and investor skepticism until clinical/program milestones or clearer financing plans are provided. Arcturus Therapeutics Q4 2025 Earnings Call Summary Q4 earnings assessment

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.